Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
1.120
-0.020 (-1.75%)
Nov 14, 2025, 4:00 PM EST - Market closed
Oragenics Employees
Oragenics had 5 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,180,948
Market Cap
4.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 0 | - |
| Dec 31, 2023 | 5 | -1 | -16.67% |
| Dec 31, 2022 | 6 | 1 | 20.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | 7 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OGEN News
- 3 days ago - Oragenics Q3 2025 Shareholder Update - Business Wire
- 25 days ago - Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Business Wire
- 5 weeks ago - Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Business Wire
- 3 months ago - Oragenics Q2 2025 Shareholder Update - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - GlobeNewsWire
- 4 months ago - Oragenics Completes Approximately $16.5 Million Offering - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - GlobeNewsWire
- 6 months ago - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewsWire